Regen BioPharma, Inc., a publicly traded biotechnology company, has appointed Dr. Harry Lander president. Lander brings extensive experience as both a researcher and administrator to the company and has served in these positions at Cornell University and Sidra Medical and Research Centre in Qatar.
Regen Appoints President
Listen to this article
Regen BioPharma, Inc., a publicly traded biotechnology company, has appointed Dr. Harry Lander president. Lander brings extensive experience as both a researcher and administrator to the company and has served in these positions at Cornell University and Sidra Medical and Research Centre in Qatar.
Keep up with the top pharma business news of the week. On the go.
More from Business
• By
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
• By
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains